At a glance
ClinicalIndex Comparison RecordN/AUnknown· 20 target
Drug / intervention
Gene-modified autologous stem cellsgenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector
In Brief
A clinical study evaluating Gene-modified autologous stem cells for Beta-Thalassemia. Targeting 20 participants across 1 site.
Detailed Summary
This is a Phase I/II clinical trial of gene transfer for treating Beta-thalassemia using a self-inactivating lentiviral vector to functionally correct the defective gene(s). The objectives are to evaluate the safety and efficacy of the gene transfer clinical protocol.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBeta-Thalassemia
CountriesChina
Collaborators--
Timeline
N/AUnknownOverdue
201820192020202120222023202420252026
First PostedNov 2017
Enrollment StartDec 2017
Primary CompletionJan 2019
Study CompletionDec 2020
TodayJul 2026
First PostedNov 24, 2017
Enrollment StartDec 1, 2017
Primary CompletionJan 1, 2019
Study CompletionDec 31, 2020
TodayJul 1, 2026
Enrollment to primary: 1.1 yearsPosted 8.6 years ago
Interventions
Gene-modified autologous stem cellsgenetic
1 infusion for 5x10\^6\~1x10\^7 gene-modified cells; or more infusions depending on the circumstances